Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
G-CONCORD randomized trial of G-CSF priming in cord blood transplantation conditioning for adult myeloid malignancies
jRCTs041180059Recruiting
- Sponsor
- The Japan Society for Hematopoietic Stem Cell Transplantation and Cellular Therapy
- Start
- Apr 2018
- Modality
- Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Randomised, open-label trial of filgrastim, cytarabine and cyclophosphamide in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (2 arms), sponsored by The Japan Society for Hematopoietic Stem Cell Transplantation and Cellular Therapy. Primary endpoint: 2-year disease-free survival. Started Apr 2018; status: recruiting.
02
Drugs
filgrastimcytarabinecyclophosphamide
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on jRCTs041180059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041180059.